Ss. Shetty et D. Delgrande, Differential inhibition of the prejunctional actions of angiotensin II in rat atria by valsartan, irbesartan, eprosartan, and losartan, J PHARM EXP, 294(1), 2000, pp. 179-186
Citations number
40
Categorie Soggetti
Pharmacology & Toxicology
Journal title
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
The effects of valsartan and other nonpeptide angiotensin II type 1 (AT(1))
receptor blockers on the prejunctional actions of angiotensin II were inve
stigated in the isolated left atria of rat. Norepinephrine stores in rat at
ria were loaded with [H-3] norepinephrine, and neuronal norepinephrine rele
ase was deduced from the radioactivity efflux. Angiotensin II (10(-9) to 10
(-6) M) produced concentration-dependent enhancement of the electrical stim
ulation-induced efflux of [H-3] norepinephrine from the preparation. Pretre
atment of tissues with valsartan, irbesartan, eprosartan, or losartan (10(-
8) to 10(-6) M) produced concentration- dependent inhibitions of the stimul
ation-induced efflux of radioactivity observed in the presence of angiotens
in II (10(-7) M). The AT(1) receptor blockers did not decrease the "basal"
stimulation-induced overflow of radioactivity but rather selectively inhibi
ted the angiotensin II-mediated augmentation of the response. Regression an
alyses of the inhibition of the angiotensin II-mediated response by valsart
an, irbesartan, eprosartan, and losartan revealed corresponding log IC50 va
lues (log M, with 95% confidence intervals) of -7.78 (-8.19, -7.51), -7.65
(-8.02, -7.40), -7.12 (-7.37, -6.86), and -6.75 (-7.00, -6.40), indicating
that the IC50 values for valsartan and irbesartan are significantly lower t
han those for eprosartan and losartan. Thus, valsartan is a potent inhibito
r of the prejunctional facilitatory effect of angiotensin II on the release
of norepinephrine from peripheral sympathetic nerves. This implies that th
e therapeutic domain of valsartan may be extended to include pathophysiolog
ical conditions such as congestive heart failure wherein prejunctional angi
otensin II receptors apparently play a significant role. Whether the high p
otency of valsartan translates into a significant clinical advantage relati
ve to the other agents tested remains to be ascertained.